LivaNova Plc - Company Profile
Powered by 
All the sales intelligence you need on LivaNova Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how LivaNova Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with LivaNova Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
LivaNova Plc (LivaNova) is a medical technology company. It mainly designs, develops, manufactures, and markets medical devices and therapies for neurological and cardiac conditions. The company’s major products include heater-coolers, oxygenators and perfusion tubing systems, cannulae, heart-lung machines, devices for neuromodulation therapy for treating DRE and DTD, autotransfusion systems, VNS therapy systems, and other related accessories. It also offers related cardiac surgery equipment and maintenance, and technical services. The company's products and services are offered to patients, clinicians, and hospitals. LivaNova distributes its products through a combination of direct sales representatives, agents, and independent distributors in the US and Europe. LivaNova is headquartered in London, Greater London, the UK.
Headquarters
United Kingdom
Address
20 Eastbourne Terrace, London, Greater London, W26LG
Website
www.livanova.com
Telephone
44 203 3250660
No of Employees
3,300
Industry
Medical Equipment
Ticker Symbol & Exchange
LIVN (NASD)
Revenue (2024)
$1.4B
10.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-483.5%
(2024 vs 2023)
Market Cap*
$4.5B
Net Profit Margin (2024)
XYZ
-446.6%
(2024 vs 2023)
* As of and is in US$
LivaNova Plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Oxygenators | VNS Therapy System |
| Extracorporeal Blood Circulation Systems | Pulse |
| Heart Lung Machines | Pulse Duo |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In March, the company secured approval from the U.S. Food and Drug Administration for the aura6000 System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea. |
| 2024 | Divestiture | In January, the company announced a wind-down of the Advanced Circulatory Support (ACS) business unit to increase the company’s strategic focus on its core Cardiopulmonary (CP) and Neuromodulation business units. |
| 2023 | Regulatory Approval | In August, the company received the US Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz In-Line Blood Monitor (ILBM), which provides accurate and continuous measurement of essential blood parameters to perfusionists throughout cardiopulmonary bypass (CPB) procedures. |
Competitor Comparison
| Key Parameters | LivaNova Plc | Abbott Laboratories | Medtronic Plc | Edwards Lifesciences Corp | Haemonetics Corp |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | Ireland | United States of America | United States of America |
| City | London | Abbott Park | Dublin | Irvine | Boston |
| State/Province | Greater London | Illinois | - | California | Massachusetts |
| No. of Employees | 3,300 | 115,000 | 95,000 | 16,000 | 3,009 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William Kozy | Chairman | Executive Board | 2018 | 74 |
| Vladimir A. Makatsaria | Chief Executive Officer; Director | Executive Board | 2024 | 53 |
| Alex Shvartsburg | Chief Financial Officer | Senior Management | 2021 | 56 |
| Anne Liddy | Chief Legal Officer | Senior Management | 2026 | - |
| Philip Kowalczyk | Chief Strategy and Corporate Development Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer